- Home
- YQ vs TSBX Comparison
YQ vs TSBX Comparison
Compare YQ & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YQ
- TSBX
- Stock Information
- Founded
- YQ 2012
- TSBX 2015
- Country
- YQ China
- TSBX United States
- Employees
- YQ N/A
- TSBX N/A
- Industry
- YQ Other Consumer Services
- TSBX
- Sector
- YQ Real Estate
- TSBX
- Exchange
- YQ Nasdaq
- TSBX Nasdaq
- Market Cap
- YQ 12.1M
- TSBX 11.2M
- IPO Year
- YQ 2020
- TSBX 2023
- Fundamental
- Price
- YQ $2.06
- TSBX $0.39
- Analyst Decision
- YQ
- TSBX Buy
- Analyst Count
- YQ 0
- TSBX 3
- Target Price
- YQ N/A
- TSBX $4.75
- AVG Volume (30 Days)
- YQ 9.2K
- TSBX 345.8K
- Earning Date
- YQ 03-19-2025
- TSBX 03-20-2025
- Dividend Yield
- YQ N/A
- TSBX N/A
- EPS Growth
- YQ N/A
- TSBX N/A
- EPS
- YQ N/A
- TSBX N/A
- Revenue
- YQ $28,507,378.00
- TSBX N/A
- Revenue This Year
- YQ N/A
- TSBX N/A
- Revenue Next Year
- YQ N/A
- TSBX N/A
- P/E Ratio
- YQ N/A
- TSBX N/A
- Revenue Growth
- YQ 22.55
- TSBX N/A
- 52 Week Low
- YQ $1.50
- TSBX $0.37
- 52 Week High
- YQ $3.20
- TSBX $5.75
- Technical
- Relative Strength Index (RSI)
- YQ 63.62
- TSBX 40.91
- Support Level
- YQ $1.93
- TSBX $0.37
- Resistance Level
- YQ $2.08
- TSBX $0.42
- Average True Range (ATR)
- YQ 0.08
- TSBX 0.04
- MACD
- YQ 0.01
- TSBX -0.00
- Stochastic Oscillator
- YQ 89.61
- TSBX 16.62
About YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers to assist students, teachers, schoolmasters, and educational authorities across China to achieve data-driven teaching, learning, and assessment. Geographically group operates in China.
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.